CVLT vs DFTX Comparison

CommVault Systems Inc provides cyber resiliency solutions designed to help the enterprise protect, secure, and recover its data, applications, and identity systems in a world of increasing cyber threats and attacks. Its offerings provide cyber resilience, including data protection, cyber recovery, data security, and governance, aiming to enable customers to continue business. The company delivers its solutions through Commvault Cloud, a cloud native platform that unifies data security, cyber recovery and identity resilience across on-premises, hybrid, multi-cloud, and software-as-a-service environments. It sells its offerings through subscription-based arrangements, including SaaS and term-based subscriptions, and also offers perpetual licenses, customer support, and professional services.

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.